MNOV -
Medicinova, Inc.
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
1.24 0.01 (0.81%) |
--- |
--- |
--- |
0.0 (0.0%) |
0.02 (1.63%) |
--- |
0.0 (0.0%) |
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
Earnings & Ratios
- Basic EPS:
- -0.07
- Diluted EPS:
- -0.07
- Basic P/E:
- -17.8571
- Diluted P/E:
- -17.8571
- RSI(14) 1m:
- 50.0
- VWAP:
- 1.25
- RVol:
- 1.7256
Events
Period |
Kind |
Movement |
Occurred At |
Related News
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
Aug 26, 2025 23:00
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
Jul 31, 2025 23:30
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
Apr 14, 2025 23:00
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
Nov 11, 2024 23:00
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Sep 30, 2024 13:00
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
Sep 09, 2024 23:00
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
Sep 03, 2024 23:00
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
Jun 20, 2024 10:00
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
Jun 05, 2024 10:00
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Jun 03, 2024 10:00